Literature DB >> 1577224

Changes in brain monoamine metabolism in rats with acute ischemic hepatic failure under artificial cardiopulmonary management.

N Murakami1, K Saito, T Kato, T Nakamura, U Moriwaki, Y Muto.   

Abstract

A study was conducted to investigate changes in monoamine metabolism in the brain of rats with acute ischemic hepatic failure (AHF) induced by two-stage hepatic devascularization. Strict artificial cardiopulmonary management was used to exclude possible confounding effects of hypotension, hypothermia and hypoxemia that often appear in AHF. Rats were put in an incubator at 34 degrees C before the ligation of the hepatic artery (second stage operation), tracheotomized and ventilated artificially throughout the remaining experimental periods. No significant difference was observed in physiological parameters, including body temperature, pulse rate and systolic arterial blood pressure or PaO2 between AHF and sham operated rats. Brain levels of norepinephrine (NE) and its metabolite 3-methoxy-4-hydroxyphenylglycol (MHPG), dopamine (DA) and its metabolites 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanilic acid (HVA), and serotonin (5-hydroxytryptamine, 5HT) and its metabolite 5-hydroxyindoleacetic acid (5HIAA) were determined by HPLC-voltametry. AHF rats showed significantly higher MHPG, DOPAC, 5HIAA and lower NE levels in the brain compared to controls. In addition, a significant negative correlation between NE and tyrosine (Tyr), a significant positive correlation between MHPG and Tyr or phenylalanine (Phe), and a significant positive correlation between DOPAC and Tyr or Phe were observed. In conclusion, the changes in monoamine metabolism in the brain of AHF rats are clearly induced specifically by hepatic failure itself, possibly through an altered metabolism of amino acids.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1577224     DOI: 10.1007/bf02777722

Source DB:  PubMed          Journal:  Gastroenterol Jpn        ISSN: 0435-1339


  12 in total

1.  Effect of body temperature on brain edema and encephalopathy in the rat after hepatic devascularization.

Authors:  P Traber; M DalCanto; D Ganger; A T Blei
Journal:  Gastroenterology       Date:  1989-03       Impact factor: 22.682

2.  Brain energy metabolism and alterations of transmitter profiles in acute hepatic coma.

Authors:  J M Funovics; J E Fischer
Journal:  J Neural Transm Suppl       Date:  1978

3.  Experimental acute hepatic encephalopathy: comparison of the electroencephalographic changes in the liverless and in the eviscerated rat.

Authors:  F Degos; J D Degos; D Bourdiau; M Peignoux; D Prandi; J Roche-Sicot; C Sicot; B Rueff; J P Benhamou
Journal:  Clin Sci Mol Med       Date:  1974-12

4.  False neurotransmitters and hepatic failure.

Authors:  J E Fischer; R J Baldessarini
Journal:  Lancet       Date:  1971-07-10       Impact factor: 79.321

Review 5.  Catecholamine metabolism: basic aspects and clinical significance.

Authors:  I J Kopin
Journal:  Pharmacol Rev       Date:  1985-12       Impact factor: 25.468

6.  Accumulation and metabolism of norepinephrine in rat hypothalamus after exhaustive stress.

Authors:  E A Stone
Journal:  J Neurochem       Date:  1973-09       Impact factor: 5.372

Review 7.  Cardiovascular, pulmonary and renal complications of fulminant hepatic failure.

Authors:  D J Bihari; A E Gimson; R Williams
Journal:  Semin Liver Dis       Date:  1986-05       Impact factor: 6.115

8.  Alteration of the turnover of dopamine and 5-hydroxytryptamine in rat brain associated with hypothermia.

Authors:  C Okuda; A Saito; M Miyazaki; K Kuriyama
Journal:  Pharmacol Biochem Behav       Date:  1986-01       Impact factor: 3.533

9.  Separate effects of low carbon dioxide and low oxygen content on rat brain monoamine metabolism during hypoxemia.

Authors:  E B Olson
Journal:  Life Sci       Date:  1988       Impact factor: 5.037

10.  Effects of hypoxia-ischemia on monoamine metabolism in the immature brain.

Authors:  F Silverstein; M V Johnston
Journal:  Ann Neurol       Date:  1984-04       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.